Bernstein Downgrades Summit Therapeutics to Underperform
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Stocks · News reference
Filed: 2026-11-18 AccNo: 0001599298-26-000094 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Summit Therapeutics has launched the HARMONi-10 global Phase III clinical trial to evaluate ivonescimab as a consolidation therapy for patients with unresectable Stage III non-small cell lung cancer.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.